 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Actelion Ltd.
 |
Actelion Ltd. |
 |
 |
 |
PROFILE |
 |
Actelion walks a fine line. The company and its subsidiaries discover and develop drugs based on their research of the endothelium, the single layer of cells between blood vessels and the blood that flows through them. The endothelium has been linked to such disorders as cancer and cardiovascular and inflammatory diseases. The firm's lead drug candidate, Valetri, failed to improve blood flow in acute heart failure patients, but Actelion is not abandoning the drug yet. The company is also developing Tracleer for congestive heart failure, along with potential treatments for other cardiovascular conditions, cancer, malaria, and Alzheimer's disease. Partners include Genentech and Johnson & Johnson.
COMPETITION |
 |
Merck & Co., Inc. (MRK)
Novartis AG (NVS)
Roche Group (ROHHY)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 19.60
1-Yr. Sales Growth: 983.2%
Employees: 227
Revenue per employee: $86,343.61
KEY PEOPLE |
 |
Jean-Paul Clozel
CEO
André J. Mueller
CFO
CONTACT INFO |
 |
Gewerbestrasse 16
CH 4123 Allschwil, Switzerland
Phone: 41-61-487-45-16
Fax: 41-61-487-45-00
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |